Endpoints News
Endpoints News looks at big studies moving GLP-1s beyond diabetes and obesity into addiction, a use the public has speculated about for years.
Recap by typeshit. Full story at Endpoints News.
Early uptake of the Wegovy pill outpaced injectable incretin weight loss drugs at a similar stage, HealthDay reported on Oct. 22.
Leftover food can't tell researchers whether someone stopped eating from fullness or from feeling sick, and Medical Xpress explains why that gap matters.
Moss says he once believed GLP-1s caused far more muscle loss than ordinary calorie cutting. He now says he got that wrong.
Topol points to neoantigens, the proteins or peptides on cancer cell surfaces, as the base of personalized cancer therapies.
Researchers found teaching emotion management alongside family behavioral treatment may help adolescents keep weight off once the program ends. No GLP-1 drugs involved.
A TriNetX analysis presented at ASCO Breakthrough found 0.20% vs 0.43% five-year cancer rates. Lead author Sarina Ailawadi says prospective studies are still needed.
Loading…